LAVA Therapeutics (NASDAQ:LVTX) Earns “Market Perform” Rating from JMP Securities

LAVA Therapeutics (NASDAQ:LVTX)‘s stock had its “market perform” rating reiterated by analysts at JMP Securities in a report released on Thursday,Benzinga reports.

Separately, HC Wainwright reissued a “neutral” rating and issued a $1.50 price target on shares of LAVA Therapeutics in a research report on Monday, March 31st. Five investment analysts have rated the stock with a hold rating, According to MarketBeat.com, LAVA Therapeutics presently has an average rating of “Hold” and an average target price of $3.17.

LAVA Therapeutics Stock Performance

NASDAQ LVTX opened at $1.25 on Thursday. The company has a market cap of $32.88 million, a P/E ratio of -1.21 and a beta of 0.46. The business’s 50 day moving average price is $1.25 and its 200-day moving average price is $1.25. LAVA Therapeutics has a fifty-two week low of $0.85 and a fifty-two week high of $2.81.

LAVA Therapeutics (NASDAQ:LVTX) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.24. As a group, equities analysts predict that LAVA Therapeutics will post -1.13 EPS for the current year.

Institutional Investors Weigh In On LAVA Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Lepercq De Neuflize Asset Management LLC acquired a new stake in LAVA Therapeutics during the first quarter worth about $29,000. XTX Topco Ltd purchased a new stake in shares of LAVA Therapeutics during the first quarter worth approximately $31,000. BNP Paribas Financial Markets purchased a new stake in LAVA Therapeutics in the 4th quarter valued at $40,000. Sanofi purchased a new position in shares of LAVA Therapeutics during the 4th quarter worth $1,825,000. Finally, BML Capital Management LLC acquired a new stake in LAVA Therapeutics during the first quarter worth $2,490,000.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.